Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip 100
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

AbbVie Inc.

www.abbvie.com

Latest From AbbVie Inc.

Bookmark
  • News

Older Patents Get Help As Federal Circuit Sides With Novartis In Gilenya, Everolimus Disputes

By Brenda Sandburg
US court finds no obviousness-type double patenting under statute that changed patent term from 17 years from issuance to 20 years from filing; decisions will impact other cases involving patents issued prior to statute.
Generic Drugs Legal Issues
Bookmark
  • News

Biosimilar Litigation Settlement Score Card: Genentech-Pfizer Herceptin Agreement Is 10th Deal

By Brenda Sandburg

Genentech inks second settlement of trastuzumab biosimilar litigation; suits ongoing against Amgen, Celltrion/Teva, and Samsung with joint claim construction proceedings.

United States BioPharmaceutical
Bookmark
  • Analysis

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

By Ian Haydock, Anju Ghangurde, Jung Won Shin and Brian Yang

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars
Bookmark
  • Analysis

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

By Ian Haydock, Anju Ghangurde, Jung Won Shin and Brian Yang

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Big Pharma
  • Parent & Subsidiaries
  • AbbVie Inc.
  • Senior Management
  • Richard A Gonzalez, Chmn. & CEO
    William J Chase, EVP, CFO
    Michael E Servino, MD, EVP, R&D & CSO
    Carlos Alban, EVP, Commercial Ops.
  • Contact Info
  • AbbVie Inc.
    Phone: (847) 937-6100
    1 N. Waukegan Rd.
    North Chicago, IL 60064
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By